

Lawrence Berkeley National Laboratory

Lawrence Berkeley National Laboratory

Title

Synthesis of oxime-linked mucin mimics containing the tumor-related TN and sialyl TN antigens

Permalink

<https://escholarship.org/uc/item/8zq9h4xp>

Authors

Marcaurelle, Lisa A.
Shin, Youngsook
Goon, Scarlett
et al.

Publication Date

2001-08-21

Peer reviewed

Synthesis of Oxime-Linked Mucin Mimics containing the Tumor-Related T_N and Sialyl T_N Antigens


Lisa A. Marcaurelle, Youngsook Shin, Scarlett Goon and Carolyn R. Bertozzi*

[†]Center for New Directions in Organic Synthesis, Departments of Chemistry and Molecular and Cell Biology, and Howard Hughes Medical Institute, University of California, Berkeley, CA 94720

bertozzi@cchem.berkeley.edu

Received Date (will be automatically inserted after manuscript is accepted)

ABSTRACT



The synthesis of oxime-linked mucin mimics was accomplished via the incorporation of multiple ketone residues into a peptide followed by reaction with aminoxy sugars corresponding to the tumor-related T_N and sialyl T_N (ST_N) antigens.

The site-specific attachment of oligosaccharides to proteins can be accomplished by reaction of nucleophilic sugar derivatives with aldehydes and ketones.¹ Previously, we reported on the use of ketone-amino acid **1** (Figure 1) for the synthesis of glycopeptide analogs containing unnatural sugar-peptide linkages.² Amino acid **1** can be prepared in one step via reductive ozonolysis of commercially available Fmoc-dehydroleucine (**2**)³ and can be incorporated into peptides (**3**) by Fmoc-based solid-phase peptide synthesis (SPPS) without need for protection

of the ketone group.⁴ The ketone group is chemically orthogonal to all naturally occurring amino acid side chain functional groups and thus can be selectively condensed with aminoxy sugars to give the corresponding oxime-linked products (**4**). Since glycoproteins often contain more than one site of glycosylation, we were interested to see if this strategy could be applied to the synthesis of glycopeptides with clustered oxime-linked glycans.

Mucins are a class of heavily *O*-glycosylated proteins that are abundantly secreted by epithelial cells specialized for mucus production.⁵ They are rich in serine and threonine residues bearing α -linked glycans initiated by *N*-acetylgalactosamine (GalNAc). A variety of carbohydrate ligands required for cell-surface interactions, including the Lewis and blood group antigens, can be presented on a

[†] The Center for New Directions in Organic Synthesis is supported by Bristol-Myers Squibb as Sponsoring Member.

¹ Reviewed in: (a) Marcaurelle, L.A.; Bertozzi, C.R. *Chem. Eur. J.* **1999**, *5*, 1384; (b) Hang, H.; Bertozzi, C.R. *Acc. Chem. Res.* **2001**, in press.

(a) Marcaurelle, L.A.; Rodriguez, E.C.; Bertozzi, C.R. *Tetrahedron Lett.* **1998**, *39*, 8417; (b) Rodriguez, E.C.; Marcaurelle, L.A.; Bertozzi, C.R. *J. Org. Chem.* **1998**, *63*, 9614.

³ Purchased from BACHEM.

⁴ Marcaurelle, L.A.; Bertozzi, C.R. *Tetrahedron Lett.* **1998**, *39*, 7279.

⁵ Reviewed in: (a) Hanisch, F.-G. *Biol. Chem.* **2001**, *143*; (b) Strous, Dekker, J. *Crit. Rev. Biochem. Mol. Biol.* **1992**, *27*, 57; (c) Carraway, K.L.; Hull, S.R. *Glycobiology*, **1991**, *1*, 131.

mucin scaffold. In cancer cells, the glycosylation pattern of mucins is altered, leading to the expression of distinct tumor-related epitopes.⁶ Thus, mucin fragments and their cancer-associated oligosaccharides have attracted much attention as components of synthetic cancer vaccines.⁷ In the present study we focused on the preparation of oxime-linked mucin mimics containing clusters of the T_N and sialyl T_N (ST_N) antigens⁸ (Figure 2), which are abundantly expressed in many types of cancer, including tumors of the breast, colon, liver and pancreas.⁹




Figure 1. Synthesis of oxime-linked glycopeptides.

We chose fragments of the endothelial mucin GlyCAM-1 (**5** and **6**, Figure 3) as peptide scaffolds.¹⁰ Peptides **5** and **6** each replace six Ser or Thr residues within the 12- or 17-amino acid sequence with amino acid **1** (designated with the single letter code “O”). The syntheses of **5** and **6** were carried out on an automated peptide synthesizer using DCC/HOBt mediated couplings, on MBHA and Fmoc-Glu(tBu)-Wang resins, respectively. Amino acid **1** was used without protection of the ketone group. Following chain assembly the peptides were cleaved from the resin

⁶ Varki, A. Glycosylation Changes in Cancer. In *Essentials of Glycobiology*; Varki, A.; Cummings, R.; Esko, J.; Freeze, H.; Hart, G.; Marth, J., Eds.; New York: Cold Spring Harbor Laboratory, 1999; pp 537-550.

⁷ Danishefsky, S.J.; Allen, J.R. *Angew. Chem., Int. Ed.* **2000**, *39*, 836.
⁸ For the synthesis of glycopeptides containing the T_N and ST_N antigens see, (a) Liebe, B.; Kunz, H. *Angew. Chem., Int. Ed.* **1997**, *36*, 618; (b) Keil, S.; Claus, C.; Dippold, W.; Kunz, H. *Angew. Chem., Int. Ed.* **2001**, *40*, 366; (c) Kuduk, S.D.; Schwarz, J.B.; Chen, X.-T.; Glunz, P.W.; Sames, D.; Ragupathi, G.; Livingston, P.O.; Danishefsky, S.J. *J. Am. Chem. Soc.* **1998**, *120*, 12474; (d) Schwarz, J.B.; Kuduk, S.D.; Chen, X.-T.; Sames, D.; Glunz, P.W.; Danishefsky, S.J. *J. Am. Chem. Soc.* **1999**, *121*, 2662; (e) Elofsson, M.; Salvador, L.A.; Kihlberg, J. *Tetrahedron* **1997**, *53*, 369; (f) George, S.K.; Holm, B.; Reis, C.; Schwientek, T.; Clausen, H.; Kihlberg, J. *J. Chem. Soc. Perkin Trans. 1* **2001**, 880.

(a) Brockhausen, I.; Yang, J.M.; Burchell, J.; Whitehouse, C.; Taylor-Papdimitriou, J. *Eur. J. Biochem.* **1995**, *233*, 607; (b) Sasaki, M.; Yamato, T.; Nakanuma, Y. *Pathol. Int.* **1999**, *49*, 325; (c) Itzkowitz, S.H.; Yaun, M.; Montgomery, C.K.; Kjeldsen, T.; Takahashi, H.K.; Bigbee, W.L.; Kim, Y.S. *Cancer Res.* **1989**, *49*, 197; (d) Itzkowitz, S.; Kjeldsen, T.; Friera, A.; Hakomori, S.-N.; Yang, U.-S.; Kim, Y.S. *Gastroenterology* **1991**, *100*, 1691.

¹⁰ Imai, Y.; Singer, M.S.; Fennie, C.; Lasky, L.A.; Rosen, S.D. *J. Cell. Biol.* **1991**, *113*, 1213.

with 95% aqueous TFA for 5 hours and precipitated from Et₂O. Analysis of the crude peptides by ESI-MS showed the desired ketone-containing derivatives as the major products.¹¹ Purification of the peptides by reversed-phase HPLC yielded targets **5** and **6** in 40-46% yield.




Figure 2. Oxime-linked analogs of the T_N and ST_N antigens.

GlyCAM-1:





Figure 3. Amino acid sequence of GlyCAM-1 and corresponding peptide fragments **5** and **6** bearing ketone-amino acid **1** (single letter code “O”) in place of Ser and Thr.

The synthesis of the aminoxy T_N antigen (**7**) was accomplished as previously described² using a phase transfer catalyzed (PTC)¹² reaction of *N*-hydroxysuccinimide (NHS) with glycosyl chloride **8**¹³ (Scheme 1). Reductive acetylation of **9**, followed by mild hydrazinolysis afforded the desired aminoxy sugar (**7**). We have recently found that the intermediate NHS

¹¹ ESI-MS (neg-ion mode): calcd for **5** 1356.1, found 1355.7; calcd for **6** 2021.8, found 2021.7.

¹² Cao, S.; Tropper, F.D.; Roy, R. *Tetrahedron* **1995**, *51*, 6679.

glycoside (**9**) can also be accessed using glycosyl bromide **10**¹³ as a donor in a Koenigs-Knorr glycosylation with NHS. While the stereoselectivity of this reaction is not as high as that achieved in the PTC reaction, the preparation of the α -bromide is generally higher yielding than the β -chloride (95% versus 45%)¹³ making this route an attractive alternative.



^aReagents: (a) NHS, (*n*Bu)₄NHSO₄, CH₂Cl₂, Na₂CO₃, 57% (α only); (b) NHS, AgClO₄, CH₂Cl₂, 4 Å MS, 67% (3:1 α/β); (c) H₂, Pd/C, Ac₂O, 100%; (d) 10% aq. N₂H₄, 71%.

The synthesis of aminoxy-ST_N **11** utilized the selectively-protected glycosyl acceptor (**12**), containing the pre-installed NHS glycoside, for reaction with known sialyl phosphite **13**¹⁴ (Figure 4). For the installation of the NHS glycoside we chose to use a Koenigs-Knorr glycosylation with glycosyl bromide **14**, which was obtained from 6-*O*-TBDPS-D-galactal (**15**).¹⁵

As depicted in Scheme 2, glycosyl bromide **14** was generated in three steps via isopropylidene formation, azidonitration¹² with CAN and NaN₃ and treatment with LiBr. Reaction of bromide **14** with NHS in the presence of AgClO₄ gave compound **16** in 65% yield as a mixture of anomers (3:1 α/β). Isolation of the desired α -glycoside (**12**) was achieved following removal of the TBDPS group with TBAF. Glycosylation of **12** with sialyl phosphite **13** using TMSOTf as the promoter gave disaccharide **17** in 44% yield as a mixture of anomers (3:1 α/β). Subsequent deprotection and reductive acetylation of **17** over a series of steps afforded the target aminoxy-ST_N **11**.





Figure 4. Retrosynthesis of aminoxy-ST_N (**11**).




^aReagents: (a) Me₂C(OMe)₂, PPTS, DMF, 50 °C, 1 h, 95%; (b) CAN, NaN₃, CH₃CN, -20 °C, 15 h, 71%, (c) LiBr, CH₃CN, rt, 5 h, 96%; (d) NHS, AgClO₄, CH₂Cl₂, 4 Å MS, rt, 2 d, 65% (3:1 α/β); (e) TBAF, AcOH, THF, rt, 6 h, 45%; (f) **13**, TMSOTf, THF, 4 Å MS, -35 °C, 1 h, 44% (3:1 α/β); (g) *p*-TsOH, MeOH, rt, o.n., 60%; (h) Ac₂O, pyridine, DMAP, rt, o.n., 54%; (i) H₂, Pd/C, Ac₂O, rt, 2 h, 49% after HPLC; (j) i) NaOMe, MeOH, rt, 24 h, ii) LiOH, MeOH, H₂O, 4 °C, o.n., iii) 10% aq. N₂H₄·H₂O, 70% for 3 steps.

¹³ Lemieux, R.; Ratcliffe, R.M. *Can. J. Chem.* **1979**, *57*, 1244.

¹⁴ (a) Sim, M.M.; Kondo, H.; Wong, C.-H. *J. Am. Chem. Soc.* **1993**, *115*, 2260; (b) Bhattacharya, S.K.; Danishefsky, S.J. *J. Org. Chem.* **2000**, *65*, 144.

¹⁵ Gervay, J.; Peterson, J.M.; Oriyama, T.; Danishefsky, S.J. *J. Org. Chem.* **1993**, *58*, 5465.



Scheme 3. Synthesis of mucin mimics **19** and **20**, containing the T_N antigen (A) and mucin mimics **21** and **22**, containing the ST_N antigen (B). All ligation reactions were performed by incubating the peptide with an excess of aminoxy sugar at 37 °C in NaOAc buffer, pH 5.5.

The ligation of **7** and **11** with peptides **5** and **6** was carried out at 37 °C with an excess of either sugar in NaOAc buffer, pH 5.5 (Scheme 3). The reactions were monitored by reversed-phase HPLC and judged to be complete after 24 h. The oxime-linked products (**19-22**) containing the T_N and ST_N antigens were purified by reversed-phase HPLC (60-70% yield) and their identity confirmed by ESI-MS.¹⁶

These syntheses illustrate that multiple clustered ketone residues can be incorporated into a peptide and reacted with aminoxy sugars. Such an approach circumvents the need to synthesize large quantities of complex glycosyl amino acids for use in peptide synthesis, a process which can be extremely labor intensive depending on the complexity of the pendant glycan. The oxime-based strategy benefits from convergent assembly of peptides and aminoxy sugars, both of which are straightforward to prepare. The incorporation of these glycopeptides into larger, full-length proteins, by techniques such as native and expressed protein ligation,¹⁷

should provide access to homogenous mucin-analogs for a variety of applications.

Acknowledgments. This research was supported by a grant from the National Science Foundation (CAREER Award CHE-9734439) and by the Laboratory Technology Research Division (SC-32), within the Office of Science, US Department of Energy under a CRADA (Cooperative Research and Development Agreement) between Lawrence Berkeley National Laboratory and CibaVision under US DOE Contract DE-AC03-76SF00098. L.A.M. thanks the ACS Division of Organic Chemistry for a graduate fellowship.

Supporting Information Available: Full experimental procedures and tabulated ¹H and ¹³C NMR data for all compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

¹⁶ ESI-MS (neg-ion mode): calcd for **19** 2665.3, found 2665.6; calcd for **20** 3331.3, found 3330.2; calcd for **21** 4412.9, found 4413.2; calcd for **22** 5078.9, found 5080.0.

¹⁷ (a) MacMillan, D.; Bertozzi, C.R. *Tetrahedron* **2000**, *56*, 9515; (b) Tilbert, T.J.; Wong, C.-H. *J. Am. Chem. Soc.* **2000**, *122*, 5421; (c) Marcaurelle, L.A.; Bertozzi, C.R. *Chem Eur. J.* **2000**, *7*, 1129; (d) Dawson, P.E.; Kent, S.B.H. *Ann. Rev. Biochem.* **2000**, *69*, 923; (e) Muir, T.W.; Sondi, D.; Cole, P.A. *Proc. Natl. Acad. Sci.* **1998**, *95*, 6705.

